Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 5

Pharmacological causes of hyperprolactinemia

Authors Daria La Torre, Alberto Falorni

Published 15 November 2007 Volume 2007:3(5) Pages 929—951

Daria La Torre, Alberto Falorni

Department of Internal Medicine, Section of Internal Medicine and Endocrine and Metabolic Sciences, University of Perugia, Perugia, Italy

Abstract: Hyperprolactinemia is a common endocrinological disorder that may be caused by several physiological and pathological conditions. Several drugs may determine a significant increase in prolactin serum concentration that is frequently associated with symptoms. The so-called typical antipsychotics are frequently responsible for drug-related hyperprolactinemia. Risperidone is one of the atypical neuroleptics most likely to induce hyperprolactinemia, while other atypical drugs are unfrequenlty and only transiently associated with increase of prolactin levels. Women are more sensitive than men to the hyperprolactinemic effect of antipsychotics. Classical and risperidone-induced hyperprolactinemia may be revert when a gradual antipsychotic drug discontinuation is combined with olanzapine or clozapine initiation. Antidepressant drugs with serotoninergic activity, including selective serotonin reuptake inhibitors (SSRI), monoamine oxidase inhibitors (MAO-I) and some tricyclics, can cause hyperprolactinemia. A long list of other compounds may determine an increase in prolactin levels, including prokinetics, opiates, estrogens, anti-androgens, anti-hypertensive drugs, H2-receptor antagonists, anti-convulsivants and cholinomimetics. Finally, hyperprolactinemia has also been documented during conditioning and after autologous blood stem-cell transplantation and during chemotherapy, even though disturbances of prolactin seem to occur less frequently than impairments of the hypothalamus-pituitary-gonad/thyroid axis after intensive treatment and blood marrow transplantation.

Keywords: anti-depressants, anti-psychotics, estrogens, opioids, prokinetics, prolactin

Download Article [PDF] 

Readers of this article also read:

Paclitaxel attenuates renal interstitial fibroblast activation and interstitial fibrosis by inhibiting STAT3 signaling

Zhang L, Xu X, Yang R, Chen J, Wang S, Yang JQ, Xiang X, He Z, Zhao Y, Dong Z, Zhang D

Drug Design, Development and Therapy 2015, 9:2139-2148

Published Date: 15 April 2015

Development of PLGA-based itraconazole injectable nanospheres for sustained release

Bian X, Liang S, John J, Hsiao CH, Wei X, Liang D, Xie H

International Journal of Nanomedicine 2013, 8:4521-4531

Published Date: 21 November 2013

Efficacy and safety of tiotropium Respimat® SMI in COPD in two 1-year randomized studies

Eric Bateman, Dave Singh, David Smith, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:197-208

Published Date: 9 June 2010

Managing anemia in lymphoma and multiple myeloma

Gunnar Birgegård

Therapeutics and Clinical Risk Management 2008, 4:527-539

Published Date: 11 April 2008

Review of erlotinib in the treatment of advanced non-small cell lung cancer

Kristen N Ganjoo, Heather Wakelee

Biologics: Targets and Therapy 2007, 1:335-346

Published Date: 15 February 2008

Update on the treatment of ankylosing spondylitis

Walter P Maksymowych

Therapeutics and Clinical Risk Management 2007, 3:1125-1133

Published Date: 15 January 2008

Review of thalidomide in the treatment of newly diagnosed multiple myeloma

Federica Cavallo, Mario Boccadoro, Antonio Palumbo

Therapeutics and Clinical Risk Management 2007, 3:543-552

Published Date: 15 September 2007

A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma

Gennaro D’Amato, Antonello Salzillo. Amedeo Piccolo, Maria D’Amato, Gennaro Liccardi

Therapeutics and Clinical Risk Management 2007, 3:613-619

Published Date: 15 September 2007

A review of rabeprazole in the treatment of acid-related diseases

Fabio Pace, Stefano Pallotta, Stefania Casalini, Gabriele Bianchi Porro

Therapeutics and Clinical Risk Management 2007, 3:363-379

Published Date: 15 July 2007